Côd QR

Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clinical trial

BackgroundLung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality worldwide. While immune checkpoint blockade (ICB), such as PD-1/PD-L1 inhibitors, have revolutionized treatment for advanced NSCLC, not all tumor patients respond to ICB therap...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Zeyu Wang, Huiyu Wang, Rui Hou, Huning Jiang, Hanfang Fan, Yuhan Zhang, Yichao Zhu, Yun Cai, Jie Mei, Junying Xu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2025-11-01
Cyfres:Frontiers in Immunology
Pynciau:
arb
Camrelizumab
immunotherapy
collagen
clinical trial
protocol
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1668782/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg